Project Grant F30CA310109
Award Date 1/15/27
Completion Date 7/15/29
Dollars Obligated $110K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
- The National Cancer Institute, an office of the Department of Health and Human Services National Institutes of Health, awarded Dana-Farber Cancer Institute, Inc. $657,443 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396, Assistance Listing R01CA315392). The award funds structural and mechanistic studies of the RAS/RAF MAPKINASE pathway to achieve atomic-resolution understanding of how these proteins recognize and interact with one another and how these interactions...
- The National Cancer Institute awarded New York University $595,993 on July 16, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop integrated biologic technologies for selective inhibition of intracellular oncoproteins. The project aims to establish a platform technology that enables direct and selective manipulation of intracellular molecules, particularly driver oncoproteins and their interactions, with the long-term goal of addressing undruggable targets in cancer....
- The National Cancer Institute awarded Duke University $693,403 in Cancer Treatment Research funding on June 9, 2026, to identify and inhibit novel downstream effectors of mutant RAS in RAS-driven cancers. The research addresses the limited treatment options for cancers carrying activating RAS mutations. KRAS is the most commonly mutated oncogene in human cancers, but existing inhibitors such as AM510 target only KRASG12C, which occurs in approximately 13 percent of lung adenocarcinoma, 3 percent...
- The National Cancer Institute awarded The University of Texas Southwestern Medical Center $131,727 on May 7, 2026, under the Cancer Research Manpower program (CFDA 93.398) to characterize a novel covalent RAS dimer in RASQ61 mutants and develop therapeutic strategies targeting those mutations commonly found in melanoma, leukemia, thyroid cancer, and lung cancer. The award funds investigator-initiated basic biomedical research focused on understanding RAS protein-protein interactions and...
- The National Cancer Institute awarded The Rockefeller University $100,228 on December 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to conduct genetic research identifying genes that function in RAS-driven cutaneous squamous cell carcinoma. The research addresses how cancer stem cells establish pro-tumorigenic microenvironments. The funded work includes three coordinated aims: identifying which cancer stem cell signature genes persist under different culture conditions;...
- Federal Grant Award Summary New York University School of Medicine received a $435,827 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective June 4, 2025, with completion targeted for May 31, 2027. The grant supports research entitled "Exploiting Synthetic Lethality to Enhance KRAS Inhibitor Therapy of Cancer," which investigates combination therapeutic strategies to overcome intrinsic and emergent resistance to...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $675,009 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop covalent inhibitors targeting RAS Q61 mutations in cancer. The research, a cross-disciplinary collaboration between investigators with expertise in RAS drug discovery and cancer modeling, focuses on developing novel covalent inhibitors of K-RASQ61C, K-RASQ61H, and N-RASQ61X oncoproteins. These mutations...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $577,331 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to repurpose HSP90 inhibitors as a condensate-directed therapy for receptor tyrosine kinase fusion-driven cancers. The project targets cancers driven by RTK fusions such as EML4-ALK and CCDC6-RET, which account for 3–5 percent of all cancer diagnoses and approximately 225,000 new lung cancer patients annually worldwide. The...
- The National Cancer Institute awarded New York University School of Medicine $684,529 in funding for Project Grant R01CA311706 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396). The award funds research on SHP2 signaling, a protein-tyrosine phosphatase implicated in Noonan syndrome and multiple neoplasms. The research employs super-resolution microscopy and mouse models to clarify how SHP2 assembles signaling complexes downstream of receptor tyrosine kinases, distinguish...
- The National Cancer Institute awarded The Rockefeller University $100,228 on December 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research characterizing multidrug resistance protein 1 (MRP1) and developing MRP1-specific inhibitors to overcome chemoresistance in cancer patients. The project addresses the role of MRP1 in exporting front-line cancer chemotherapeutics and its association with lower survival rates across multiple cancer types. The research...